If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== Commercial ==== WNCB-FM (93.9 B939 FM, Country) WQDR-FM (94.7QDR, Country) WDCG-HD2 (ALT 95.3, Throwback Hits, analog broadcast on 95.3 FM W237BZ) WBBB-FM 96.1 (Radio 96.1, Adult hits) WPLW-FM (96.9 Pulse FM, Contemporary hits) WQOK-FM (K97.5, Hip hop) WRDU-FM (100.7, Classic rock) WRAL-FM (Mix 101.5, Adult contemporary) WKIX-FM (KIX 102.9, Classic hits) WNNL-FM (103.9 The Light, Urban contemporary gospel) WDCG-FM (G105, Contemporary hit radio) WTKK-FM (106.1 FM, News/Talk) WFXC-FM/WFXK-FM (Foxy 107/104, Urban adult contemporary) WQDR-AM (570, classic rock) WPTF-AM (NewsRadio 680, News/Talk) 750 WAUG (Hot 97.9, Mainstream urban WKIX (Just Right Radio 850 and 93.5 FM, Popular standards)
== Prolactin == Agonists: Growth hormone Human placental lactogen Placental growth hormone (growth hormone variant) Prolactin S179D-hPRL Somatotropin Antagonists: Δ1–9-G129R-hPRL Δ1–14-G129R-hPRL G120K-hGH G129R-hPRL Prolactin modulators: Prolactin inhibitors: D2 receptor agonists (e.g., bromocriptine, cabergoline); Prolactin releasers: D2 receptor antagonists (e.g., domperidone, metoclopramide, risperidone) Estrogens (e.g., estradiol) Progestogens (e.g., progesterone)
Mild-to-moderate benign prostatic hyperplasia and lower urinary tract symptoms Pattern hair loss in both men and women 5-ARIs can be used in the treatment of hirsutism in women. The usefulness of 5-ARIs for the potential treatment of acne is uncertain. 5-ARIs are sometimes used as antiandrogens in feminizing hormone therapy for transgender women to help reduce body hair growth and scalp hair loss. They have also been explored in the treatment and prevention of prostate cancer. While the 5-ARI finasteride reduces the cancer risk by about a third, it also increases the fraction of aggressive forms of prostate cancer. Overall, there does not seem to be a survival benefit for prostate cancer patients under finasteride.
Coenzyme Q (CoQ ), also known as ubiquinone, is a naturally occurring biochemical cofactor (coenzyme) and an antioxidant produced by the human body. The human body mainly produces the form known as coenzyme Q10 (CoQ10, ubidecarenone), but other forms exist. CoQ is used by and found in many organisms, including animals and bacteria. As a result, it can also be obtained from dietary sources, such as meat, fish, seed oils, vegetables, and dietary supplements. CoQ plays a role in mitochondrial oxidative phosphorylation, aiding in the production of adenosine triphosphate (ATP), which is involved in energy transfer within cells. The structure of CoQ10 consists of a benzoquinone moiety and an isoprenoid side chain, with the "10" referring to the number of isoprenyl chemical subunits in its tail. Although a ubiquitous molecule in human tissues, CoQ10 is not a dietary nutrient and does not have a recommended intake level, and its use as a supplement is not approved in the United States for any health or anti-disease effect.
== History == Rugby league started in Australia in the period 1907–08. The Australian Rugby Football League Board of Control was formed by the New South Wales Rugby League (NSWRL) and Queensland Rugby League (QRL) in December 1924 to administer the running of the national team. George Ball was the first secretary of the Board and John La Maro the first chairman. Prior to this time, the international rugby league was organised jointly by the NSWRL and the QRL. It was only after this time that the Australian team began to wear the now-familiar sporting colours of Green and Gold. Since 1924, rugby league bodies in all other states and territories became affiliated to the Board of Control and ARL. Until 1984 the ARFL Board of Control was effectively run by the NSWRL board, and many Queensland players and administrators throughout this period believed that the NSWRL used this power to the detriment of Queenslanders, especially with respect to national team selection. In 1986 the ARL was incorporated under the name Australian Rugby Football League Limited as a separate entity and Ken Arthurson was the first executive chairman of the new body. With national expansion of the competition implemented for the 1995 season the NSWRL passed control of the Winfield Cup competition to the ARL. Following Kerry Packer's announcement that his Optus Vision company owned both free-to-air and pay television broadcasting rights for the sport in Australia, News Corporation, controlled by Rupert Murdoch, undertook a bold bid to create a rival competition, Super League (Australia).
Sources: en.wikipedia.org
Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. It has been found effective in several randomized clinical trials, including in the United States and New Zealand, and is being investigated in additional trials in the United States and a non-inferiority trial in Australia in which it is being compared head-to-head with the smoking cessation aid varenicline (sold in the United States as Chantix). It has also been used entheogenically via mescalbeans by some Native American groups, historically in the Rio Grande Valley predating even peyote. Cytisine is on the World Health Organization's List of Essential Medicines.
According to Fuhrman, the ship naturalists J. R. Forster and Georg Forster spent so much time drawing and describing the fish that only the roe and liver were cooked. The three men experienced numbness and weakness in their limbs, only surviving the incident due to the small amount they ingested. The toxin was first isolated and named in 1909 by Japanese scientist Dr. Yoshizumi Tahara. It was one of the agents studied by Japan's Unit 731, which evaluated biological weapons on human subjects in the 1930s.
In organic chemistry, a carboxylic acid is a polar, organic acid that contains a carboxyl group (−C(=O)−OH) attached to an R-group. The general formula of a carboxylic acid is often written as R−COOH or R−CO2H, sometimes as R−C(O)OH, with R referring to an organyl group (e.g., alkyl, alkenyl, aryl), or hydrogen, or other groups. Carboxylic acids occur widely. Important examples include the amino acids and fatty acids. Deprotonation of a carboxylic acid gives a carboxylate anion. Carboxylic acids are often considered weak acids as they only partially ionise (dissociate) in water.
== Van Deemter equation == The van Deemter equation relates height equivalent to a theoretical plate (HETP) of a chromatographic column to the various flow and kinetic parameters which cause peak broadening, as follows:
=== Launch === At 8:04:13 a.m. EST, May 15, 1963, Faith 7 was launched from Launch Complex 14. At T+60 seconds, the Atlas started its pitch program. Shortly afterward, MA-9 passed through max Q. At T+2 minutes 14 seconds Cooper felt BECO (Booster Engine Cutoff) and staging. The two Atlas booster engines had been left behind. The Launch Escape Tower was then jettisoned. At T+3 minutes the cabin pressure sealed at 5.5 psi (38 kPa). Cooper reported, "Faith 7 is all go."
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.